ePedigree Requirements to Take a Few More Years - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePedigree Requirements to Take a Few More Years


ePT--the Electronic Newsletter of Pharmaceutical Technology

Sacramento, CA (Oct. 9)—The electronic pedigree mandate for prescription drugs has been delayed again. California Gov. Arnold Schwarzenegger signed legislation that delays ePedigree implementation until 2015.

The deadline was first pushed back last March, from January 2009 to January 2011. Now, manufacturers will have another few years to comply with the new requirement.

Under the act, S.B. 1307, a manufacturer selling drugs in California must have an ePedigree for 50% of the drugs it sells in the state by 2015. As of July 2016, wholesalers or repackagers will be prohibited from selling, trading, or transferring a dangerous drug without a pedigree or from acquiring a dangerous drug without receiving a pedigree; the same rule will go into effect for pharmacies in July 2017. A pharmacy warehouse will not be able to acquire a dangerous drug without receiving a pedigree, as of July 2017.

Industry has been keeping an eye on California’s ePedigree rules as they are likely to impact all US manufacturers and set the stage for a national ePedigree standard. It now looks like companies have more than enough time to prepare.

Read the full legislation here.

Read more about ePedigrees:

ePedigree: Using the Gift of Time Wisely

Epedigree in the Pharmaceutical Supply Chain

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here